カテゴリー「がん」の53件の記事

2011年10月19日 (水)

G:日本人のがん“半分は予防可能” NHKニュース

リンク: 日本人のがん“半分は予防可能” NHKニュース.

ものすごく久しぶりの更新です...。


(以下引用)


日本人のがん“半分は予防可能”
10月19日 5時25分

日本人のがんは、喫煙やウイルスなどの感染によるものが多く、半分は予防できる原因で起きているとする調査結果を国立がん研究センターがまとめました。

国立がん研究センターのグループは、平成17年にがんと診断された人の数を、がんのリスクを押し上げる喫煙や飲酒の習慣、それにウイルスの感染などがある人の数と照らし合わせ、日本人全体のがんの原因を分析しました。

その結果、がんの原因で最も多いのは、男性の場合▽喫煙で29.7%、次いで▽肝炎ウイルスやピロリ菌などの感染で22.8%、続いて▽飲酒で9%でした。

また女性で最も多いのは▽感染で17.5%、次いで▽喫煙で5%、▽飲酒で2.5%となっていました。

男女合わせると、がんの半分ほどは、こうした予防できる原因で起きているということで、グループでは「生活習慣や環境の改善で日本人のがんは確実に減らせる」としています。

一方、肥満が原因となるがんは、日本人の場合、男性で0.8%、女性で1.6%と少なく、アメリカ人の3分の1程度だったということです。国立がん研究センターの津金昌一郎予防研究部長は、「今回の結果は日本人のがん全体を統計的に分析したものだが、個人レベルでもがんの要因のある人は、リスクを減らすよう努力して欲しい」と話しています。

| | コメント (0) | トラックバック (0)

2011年2月17日 (木)

G ビスフォスフォネートは,大腸癌になるリスクを減らす:Popular Bone Drugs Linked to Reduced Colon Cancer Risk - Yahoo! News

リンク: Popular Bone Drugs Linked to Reduced Colon Cancer Risk - Yahoo! News.

骨粗鬆症の治療などに使われるビスフォスフォネートは,大腸癌になるリスクを減らす可能性がある。スタチン系抗コレステロール薬と類似した作用機序。乳癌のリスクを減らす可能性も。

TUESDAY, Feb. 15 (HealthDay News) -- People who take drugs called bisphosphonates to prevent bone loss may also reduce their risk of developing colorectal cancer by almost 60 percent compared to those not on the drugs, a new study suggests.

Bisphosphonates include such common drugs as Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate) and Reclast (zoledronic acid). These drugs work by increasing bone thickness, thereby reducing the risk of fractures, the researchers said.

In prior studies, bisphosphonates have already been shown to be associated with a reduced odds for breast cancer.

"These [new] findings are meaningful because they point to a possible protective effect of this class of drugs being relevant to prevention of many different cancers," said lead researcher Dr. Gad Rennert, from the Technion-Israel Institute of Technology Faculty of Medicine and chairman of the department of community medicine and epidemiology at the Carmel Medical Center of Clalit Health Services in Haifa, Israel.

"This is [similar] to the effect that we and others have shown for [cholesterol-lowering] statins," he said, noting that "bisphosphonates and statins share the same metabolic pathway."

The results of the U.S. National Cancer Institute-supported study are published in the Feb. 14 issue of the Journal of Clinical Oncology.

For the study, Rennert's team collected data on almost 1,900 postmenopausal women who took part in the Molecular Epidemiology of Colorectal Cancer study, which is a population-based trial in northern Israel.

The researchers found that taking bisphosphonates, mostly Fosamax, for at least a year was associated with a significant 59 percent reduction in relative risk for colorectal cancer.

"The magnitude of the reduced risk is less important because this is an association study; however, it is very significant after controlling for a dozen other known risk factors," Rennert said.

They took into account factors such as family history, ethnic background, diet, physical activity, weight, vitamin D consumption and the use of other drugs such as aspirin, statins and hormone replacement therapy.

The findings in this study show that bisphosphonates are associated with a reduced risk of developing colorectal cancer, but they cannot confirm a causal effect -- that is, the study doesn't prove that the use of bisphosphonates is responsible for the lower risk of colorectal cancer.

However, the lowered risk of colorectal cancer seen with bisphosphonates may be due to the way the drug acts in the body, which is similar to how cholesterol-lowering drugs called statins work, according to Rennert. These same researchers also found in another study that statin use also reduced the risk of colorectal cancer, he noted.

"We also found a similar effect last year with risk of breast cancer, which has already been replicated by three other groups," Rennert added.

A randomized trial is need to prove that bisphosphonates are protective against colorectal cancer, Rennert said. "It should be relatively easy, as it seems that all that is needed is a year of treatment to see the effect," he said.

The researchers noted, however, that the risks of using bisphosphonates include the possibility, in rare cases, of osteonecrosis of the jaw (destruction of the jawbone or jaw tissue). Bisphosphonates used for osteoporosis have also been linked to a rare fracture of the thigh, according to the U.S. Food and Drug Administration.

"The adverse effects profile is of major importance if bisphosphonates are going to be recommended for cancer prevention in healthy people," the study authors cautioned.

Commenting on the study, Eric Jacobs, Strategic Director of Pharmacoepidemiology at the American Cancer Society, said that "the lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing."

However, these results should be interpreted with caution and require confirmation by additional studies, he said. "Results from the only other study of bisphosphonate use and colorectal cancer, a recent large study from the United Kingdom, do not support an important protective effect," Jacobs noted.

Fortunately, there are other proven ways to help lower risk of colorectal cancer, he said. "In particular, all Americans, 50 or older, should get a screening test so that precancerous polyps can be detected and removed before they turn into cancer."

| | コメント (0) | トラックバック (0)

2011年2月15日 (火)

G がん保険は通院重視型にシフト:楽コレ! 経済ナビ:生保各社「入院より通院に手厚く」 がん保険、開発競争 - 毎日jp(毎日新聞)

リンク: 楽コレ! 経済ナビ:生保各社「入院より通院に手厚く」 がん保険、開発競争 - 毎日jp(毎日新聞).

がん保険も入院から通院重視へ,という流れへようやく変わってきたという記事です。通院型,一時金型,収入保障型が紹介されています。

(以下,引用です)

経済ナビ:生保各社「入院より通院に手厚く」 がん保険、開発競争
2010年12月 7日

生命保険各社が新しいがん保険の開発、販売に力を入れている。医療技術の進歩などで治療形態が入院から通院へシフトしていることを受け、通院給付金を手厚くしているのが特徴だ。人口減で主力の死亡保険が伸び悩む中、がん保険分野の競争は激しくなる一方。患者のニーズをいかに的確につかめるかを巡り、各社がしのぎを削っている。【和田憲二】

 「せめてお金の心配なしで治療に専念したかった」。大阪府高槻市の女性(61)は自らの闘病生活を悔やんでいる。12年前に乳がんで3日間入院し、約7ミリの腫瘍を切除。退院後2カ月は毎日通院し、放射線治療を受けた。転移・再発の恐れから術後5年間は隔週の通院と連日の服薬を強いられた。
 女性はがん保険に加入しており、がんと診断された際に診断給付金100万円(入院・手術費込み)を受け取った。だが、通院給付金は5日以上の入院が条件のため受け取れず、治療費を保険で賄うことはできなかった。

 ◇入院日数12日減

 従来型のがん保険は入院日数に応じた給付に主眼を置いてきた。通院給付金が支払われる場合でも一定の入院が条件だったり、通算の給付日数に制限がある場合が大半。だが、医療技術の進歩や国の医療費削減で、近年は抗がん剤や放射線の治療でも入院せず、通院で対応するケースが増加。厚生労働省によると、がん治療の平均入院日数は02年の35・7日から08年は23・9日に減り、がん患者に占める通院治療者の割合は46・2%から52・5%に増えた。

 こうした流れを受け、損保ジャパンひまわり生命保険は11月2日、入院なしでも通院給付金を受け取れるがん保険を発売した。年間120日を限度に、主要ながんの治療法なら何年間でも保障する。

 同社は「通院が長引いても安心して治療に専念できる」と強調、現在の20倍の年間10万件の新契約獲得を目指す。

 ◇「有望分野」

 入院・通院以外の保障を手厚くした商品の投入も相次ぐ。富士生命保険は10月、診断給付金を従来の10倍となる最高1000万円まで支払うがん保険を発売した。診断直後にまとまった額の保険金を給付することで、治療法を幅広く検討できるようにした。

 アクサ生命保険は6月、がんの診断時から5年間、年金を受け取れる「収入保障」型を発売。「働き盛りの世代の契約が伸びている」(同社)という。

 生命保険協会によると、09年度のがん保険の年間新契約数は04年度比約3割増の126万6000件と「頭打ちとなっている国内生保市場で数少ない有望分野」(大手生保)。今後も治療形態の変化に合わせた商品開発が加速しそうだ。

.....................................................................................................................

 ■ことば

 ◇がん保険

 がんと診断されたり、がんで入院、治療を受けた場合や死亡した際に保険金が支払われる民間保険。74年に米アメリカンファミリーが初めて発売。外資系を保護するため、国内大手の販売は認められていなかったが、01年1月に大手国内生保や損保系生保、同7月に大手国内損保参入が解禁された。

| | コメント (0) | トラックバック (0)

2011年1月24日 (月)

G がん患者はこれまで考えられていたほどには,うつ症状で苦しんでいないようだ:Fewer Cancer Patients May Be Depressed Than Thought - Yahoo! News

リンク: Fewer Cancer Patients May Be Depressed Than Thought - Yahoo! News.

がん患者では,これまで考えられているほどには,うつ症状に陥っている人は少ないという国際研究です。うつや不安を訴える人の割合は,緩和医療を受けている人と受けていない人で違いがなかった,という結果に基づいています。うつまではいかなくても気分障害になっている人は多いようであり,さらに,当然ですがうつはがんの重大な合併症であることを,医療者は認識すべきことが強調されています。がんの生存率が高くなっていること,欧米と日本では患者のがんのとらえ方が多少異なるようなので同じことが日本でもいえるのか,など,気になるところです。

THURSDAY, Jan. 20 (HealthDay News) -- The rate of depression among cancer patients may be lower than previously believed, a new study indicates.

An international team of researchers analyzed 94 studies involving more than 14,000 patients and found that about one-sixth of cancer patients suffer depression and about one-third have a more widely defined mood disorder.

Only modest rates of depression and anxiety occurred in cancer patients in the first five years after diagnosis, which suggests that depression is not inevitable in these patients, the researchers said.

Only when it was combined with other mood disorders was depression common, occurring in 30 percent of hospitalized cancer patients.

The study is published online Jan. 19 in The Lancet Oncology.

Rates of depression and anxiety were not significantly different between patients receiving palliative care (care designed to ease pain and increase comfort in patients with terminal cancer) or non-palliative care (care designed to fight the cancer while easing symptoms). This suggests that the effects that differences in cancer care settings and possibly cancer stage have on depression may have been previously overemphasized, the researchers said in a journal news release.

They also concluded that cancer patients' age and sex do not influence their risk of depression.

"Although these rates (of depression) are modest, this group of patients should not be overlooked. Improvements in survival and high prevalence of most cancers actually increase rates of depression, amounting to what we estimate to be 340,000 people in the UK and 2 million in the USA with major depression and cancer at any time," noted the researchers in the release.

"Our study shows that depression alone is not as common as previously thought in cancer settings, occurring in one in six patients, about the same as the rate seen in primary care settings. Although depression remains an important and overlooked complication of cancer, clinicians must also be vigilant for other related emotional problems such as anxiety, adjustment disorder or simply any form of significant distress," concluded the researchers, who stressed that "there is still an urgent need" for screening programs to detect depression, anxiety and mood disorders among cancer patients.

| | コメント (0) | トラックバック (0)

2011年1月20日 (木)

B イレッサ被害「防げたはず」 : 医療ニュース : yomiDr./ヨミドクター(読売新聞)

リンク: イレッサ被害「防げたはず」 : 医療ニュース : yomiDr./ヨミドクター(読売新聞).

ちょうど昨日(1月19日),東京駅でイレッサ関連の抗議行動をみかけました。また,ちょうど昨日はテレビでも,海外で使用されている新薬承認の省略化に関する番組がくまれていました。いろいろと難しい問題が含まれています。

(以下引用)
元薬系技官トップが厚労省批判
 肺がん治療薬イレッサ(一般名ゲフィチニブ)の副作用で死亡した患者の遺族らが国とアストラゼネカ社に損害賠償を求めた訴訟で、東京・大阪両地裁が被告の救済責任を認め和解を勧告したことについて、旧厚生省の薬系技官トップだった土井脩氏(67)が読売新聞の取材に応じ、イレッサを巡る厚生労働省の審査・安全対策の問題点を指摘し、早期解決を求めた。

 薬務行政の元責任者が古巣の施策を批判するのは異例で、波紋を広げそうだ。

 土井氏は、イレッサ問題が起きる前年の2001年1月まで、医薬安全担当審議官を務めた。1993年、抗ウイルス剤ソリブジンと抗がん剤を併用した患者が死亡した薬害の発生当時は、安全対策の担当課長だった。

 イレッサは02年7月、世界に先駆けて日本で承認されたが、まもなく間質性肺炎の副作用で死亡例が次々に報告された。土井氏は「最初に承認したのはよいが、前後の対応が問題。行政がやるべきことをやっていれば被害はかなり防げたはず」と話す。間質性肺炎については審査で指摘され、薬の添付文書にも盛り込まれたが、目立たない記載で現場に浸透しなかった上、その後の安全対策にも問題があった、という。

 まず承認の際、条件として全例調査を義務づけなかったのを「間違い」と言う。全例調査は、懸念のある薬の場合、使える医師を限定し、すべての投与患者を把握して、承認後も安全監視を続ける仕組み。土井氏は「イレッサにはこの条件が付かず、無防備に使用が拡大した」と指摘する。

 事後の対策では、「重大な副作用報告があったら迅速に対応すべきだ。イレッサの場合、緊急安全性情報を出して現場に注意喚起するまで3か月もかかった」と問題視する。ソリブジン薬害では、報告1週間後に緊急安全性情報が出た。

 厚労省は、今回の裁判で国の責任を認めると、薬の審査を慎重にせざるを得なくなり、抗がん剤などの承認が難しくなるとの懸念を示している。

 土井氏は「国があつものに懲りてなますを吹く対応をせず、懸念材料があれば条件つきで承認し、責任を持って審査から市販後まで一貫した安全対策を強化すれば、そんな問題は起きない」と断言。「裁判で無駄な時間を費やすより、患者の立場に立った対策に力を尽くすべきだ」と語った。

 地裁和解勧告でも土井氏同様の所見

 イレッサ訴訟で東京地裁が7日に示した和解勧告では、土井氏の指摘通り、ソリブジン薬害の教訓が生かされなかったことを問題視する所見が示されていた。

 イレッサの添付文書では、間質性肺炎についての記載が「重大な副作用」を示す欄の4番目と、目立たない扱いだった。ソリブジンもイレッサ同様、添付文書の記載が医療現場で見落とされ、被害につながった。ソリブジン薬害を契機に、重要な事項は前に記すよう添付文書の記載要領が改められたが、イレッサで同じ過ちが繰り返された。

 所見はソリブジン薬害に触れた上で、「(イレッサでも)重大な副作用欄の初めに記載したうえ、致死的なものとなりうることについて記載する行政指導を行うことが適切であった」などと指摘した。和解勧告への回答期限は今月28日。原告は受け入れを表明したが、被告は国、アストラゼネカ社とも態度を保留している。

(2011年1月19日 読売新聞)

| | コメント (0) | トラックバック (0)

2011年1月 6日 (木)

G 抗がん剤の最大の欠点カプセルで克服…東大開発 : 科学 : YOMIURI ONLINE(読売新聞)

リンク: 抗がん剤の最大の欠点カプセルで克服…東大開発 : 科学 : YOMIURI ONLINE(読売新聞).

(以下引用)

人体が医薬品を異物として解毒したり、がん細胞が抗がん剤を排出したりする防御網をかいくぐり、抗がん剤をがん細胞の奥まで運べる微細カプセルの開発に、東京大などが成功した。

 効率的ながん治療を可能にする成果で、米医学誌サイエンス・トランスレーショナル・メディシンに6日発表する。

 カプセルの大きさは、ウイルスとほぼ同じ直径10万分の4ミリ・メートル。表面が水になじむよう素材を工夫し、血液中にまぎれさせて人体の免疫機能に捕捉されないようにした。また、薬剤耐性を獲得したがん細胞は少ない分子からなる抗がん剤を外へ排出するポンプのような構造を持つため、細胞が取り込む栄養分に見せかけるよう、分子の数が多いカプセルを設計した。

 その結果、カプセルはがん細胞の遺伝子が収納された核の近くまで届いて初めて破壊されるようになり、抗がん剤が遺伝子の働きを邪魔してがん細胞の増殖を抑制できるようになった。

 開発した片岡一則教授は「カプセルは『トロイの木馬』のように、がん細胞に気付かれず入り込める。様々なタイプの抗がん剤が利用できるので、治療の幅が大きく広がる」と話している。

| | コメント (0) | トラックバック (0)

2010年12月 8日 (水)

G アスピリンの日常服用でがん予防:BBC News - Small daily aspirin dose 'cuts cancer risk'

リンク: BBC News - Small daily aspirin dose 'cuts cancer risk'.

少量のアスピリンを毎日服用することで,がん発症を防止できる。患者はアスピリン服用に伴う有害作用を上回る利益を得ることができる。

A small daily dose of aspirin - 75mg - substantially reduces death rates from a range of common cancers, a study suggests.

Research at Oxford University and other centres found that it cut overall cancer deaths by at least a fifth.

The study, published in the Lancet, covered some 25,000 patients, mostly from the UK.

Experts say the findings show aspirin's benefits often outweighed its associated risk of causing bleeding.

Aspirin is already known to cut the risk of heart attack and stroke among those at increased risk. But the protective effects against cardiovascular disease are thought to be small for healthy adults, and aspirin increases the risks of stomach and gut bleeds.

However, this latest research shows that when weighing up the risks and benefits of taking aspirin, experts should also consider its protective effect against cancer.

Those patients who were given aspirin had a 25% lower risk of death from cancer during the trial period and a 10% reduction in death from any cause compared to patients who were not given the drug.

Lasting protection

The treatment with aspirin lasted for between four and eight years, but long term-follow-up of around 12,500 patients showed the protective effect continued for 20 years in both men and women.

Lead researcher Professor Peter Rothwell said the findings might well underestimate the reduction in deaths that would result from longer-term treatment with aspirin.

The risk of cancer death was reduced by 20% over 20 years. For individual cancers the reduction was about 40% for bowel cancer, 30% for lung cancer, 10% for prostate cancer and 60% for oesophageal cancer.

The reductions in pancreas, stomach and brain cancers were difficult to quantify because of smaller numbers of deaths.

There was also not enough data to show an effect on breast or ovarian cancer and the authors suggest this is because there were not enough women in the trials. Large-scale studies investigating the effects on these cancers are under way.

Professor Rothwell said he was not urging healthy middle-aged adults to immediately start taking aspirin, but said the evidence on cancer "tips things towards it being well worth it". The benefit in cancer reduction were found from a low daily dose of 75mg.

Professor Rothwell said the annual risk of major internal bleeding was about 1 in 1,000 and aspirin roughly doubled that risk. But he said the danger of major bleeding was "very low" in middle age but increased dramatically after 75.

A sensible time to consider starting daily aspirin use would be between 45-50, continuing for around 25 years, he said.

Cancer Research UK described the results as "promising". But Ed Yong, head of health information and evidence, said: "We encourage anyone interested in taking aspirin on a regular basis to talk to their GP first."

Professor Peter Elwood, an epidemiologist from Cardiff University, who carried out some of the first studies into the effects of aspirin on health, said individuals should make up their own minds:

"Aspirin should be thought of in the same context as lifestyle changes such as diet and exercise which can help to preserve health."

Professor Elwood said taking aspirin at night and with calcium seemed to enhance its effects. He suggested taking it with a glass of milk as this could also reduce stomach irritation.

| | コメント (0) | トラックバック (0)

2010年12月 4日 (土)

B 果物や野菜を多く摂取しても,がんの発症を防げるわけではない。British Journal of Cancer - Fruit and vegetables and cancer risk

リンク: British Journal of Cancer - Fruit and vegetables and cancer risk.

果物や野菜を多く摂取しても,がんの発症を防げるわけではない。肥満,アルコール摂取,タバコなどの危険因子を除去することに努めるべし。

(Abstract)
The possibility that fruit and vegetables may help to reduce the risk of cancer has been studied for over 30 years, but no protective effects have been firmly established.

For cancers of the upper gastrointestinal tract, epidemiological studies have generally observed that people with a relatively high intake of fruit and vegetables have a moderately reduced risk, but these observations must be interpreted cautiously because of potential confounding by smoking and alcohol.

For lung cancer, recent large prospective analyses with detailed adjustment for smoking have not shown a convincing association between fruit and vegetable intake and reduced risk.

For other common cancers, including colorectal, breast and prostate cancer, epidemiological studies suggest little or no association between total fruit and vegetable consumption and risk. It is still possible that there are benefits to be identified: there could be benefits in populations with low average intakes of fruit and vegetables, such that those eating moderate amounts have a lower cancer risk than those eating very low amounts, and there could also be effects of particular nutrients in certain fruits and vegetables, as fruit and vegetables have very varied composition.

Nutritional principles indicate that healthy diets should include at least moderate amounts of fruit and vegetables, but the available data suggest that general increases in fruit and vegetable intake would not have much effect on cancer rates, at least in well-nourished populations.

Current advice in relation to diet and cancer should include the recommendation to consume adequate amounts of fruit and vegetables, but should put most emphasis on the well-established adverse effects of obesity and high alcohol intakes.

| | コメント (0) | トラックバック (0)

2010年11月 9日 (火)

がん冊子「患者必携」

リンク: がん「患者必携」知って…栃木県が公開講座 : 医療ニュース : yomiDr./ヨミドクター(読売新聞).

国が、がん患者に必要な情報をまとめた冊子「患者必携」が完成し、県内の相談窓口を載せた「地域の療養情報・栃木」と合わせ、インターネット(http://ganjoho.jp)で公開を始めた。

 県は7日、患者必携の普及を図る公開講座を宇都宮市の県立がんセンターで開き、患者や医療関係者ら約180人が参加した。

 国は2007年、がん死亡者の20%減を目標としたがん対策推進基本計画を策定し、その中で「がん医療に関する相談支援・情報提供」の強化方針を打ち出している。患者必携は、情報提供の一環として国立がん研究センターがまとめた。

 3冊で構成、がんと診断されて間もない患者にがんとの向き合い方をアドバイスする「がんになったら手にとるガイド」や、患者が医師から受けた説明や質問事項を書き込む「わたしの療養手帳」などがある。このほか、栃木、茨城、静岡、愛媛4県では、試行的に「地域の療養情報」を製作。栃木版では、県内6か所のがん診療連携拠点病院や、相談支援センターの連絡先も掲載している。患者必携は、現在はまだインターネット上でしか公開していないが、来年1月頃から、印刷した冊子も書店や病院売店などで販売していく予定という。

 7日に開かれた公開講座では、国立がん研究センターの渡辺清高・がん対策情報センター室長が基調講演した。患者必携の活用法などを説明し、「患者さんがどこの機関に何を相談すべきかを知る手がかりになると思う」と話した。また、コメンテーターとして出席した県看護協会の河野順子会長は「患者さんが一番接するのは看護師。我々も患者必携の内容を理解して、看護に臨みたい」と語った。

(2010年11月8日 読売新聞)

| | コメント (0) | トラックバック (0)

2010年11月 7日 (日)

Red meat linked to esophageal, stomach cancer risks | Reuters

リンク: Red meat linked to esophageal, stomach cancer risks | Reuters.

Reuters Health - Red-meat lovers may have a greater likelihood of developing certain cancers of the throat and stomach than people who limit their intake of steaks and hamburgers, a new study suggests.

Researchers found that among nearly 500,000 older U.S. adults followed for a decade, only a small number developed cancers of the esophagus or stomach. However, the risks were relatively greater among those who ate a lot of red meat, or certain compounds generated from cooking meat.

Overall, study participants in the top 20 percent for red-meat intake were 79 percent more likely than those in the bottom 20 percent to develop esophageal squamous cell carcinoma -- a cancer that arises in the lining of the upper part of the esophagus.

Meanwhile, the risk of a type of cancer in the upper portion of the stomach near the esophagus (gastric cardia) was elevated among men and women with the highest estimated intake of one form of heterocyclic amine (HCA). HCAs are compounds that form when meat is cooked using high-temperature methods, such as grilling over an open flame; they have been found to cause cancer in lab animals.

The findings, reported in the American Journal of Gastroenterology, do not prove that red meat promotes the two cancers, the researchers emphasize.

But the results add to what has been an uncertain body of evidence on the link between red meat and esophageal and stomach cancers.

A 2007 research review by the World Cancer Research Fund and American Institute for Cancer Research, both non-profit groups, concluded that red and processed meats were associated with a "limited suggestive increased risk" of esophageal cancer.

The report also said there was a similar level of evidence for a link between processed meats and stomach cancer, and insufficient data on whether red meat intake is connected to the cancer at all.

However, most of the studies considered in the report were so-called case-control studies, where researchers ask patients with a given disease about their past lifestyle habits and other health factors, then compare them to a group of healthy individuals.

That type of study design can offer only limited evidence about whether a particular exposure -- like red meat in the diet -- is related to a disease risk, explained Dr. Amanda J. Cross, a researcher at the U.S. National Cancer Institute who led the new study.

Studies with prospective designs, which follow initially healthy people over time, provide stronger evidence.

In addition, most earlier research did not look at meat intake and different subtypes of esophageal and stomach cancers. That is important, Cross told Reuters Health, because the different subtypes seem to have different risk factors.

So for their study, Cross and her colleagues prospectively followed 494,979 U.S. adults ages 50 to 71 over roughly 10 years. At the outset, participants completed detailed questionnaires on their diets -- including the methods they typically used for cooking meat, and the usual level of "doneness" they preferred -- as well as other lifestyle factors.

Over the next decade, 215 study participants developed esophageal squamous cell carcinoma; that included 28 cases among the bottom 20 percent for red-meat intake, and 69 cases in the top 20 percent.

Another 454 men and women were diagnosed with gastric cardia cancer. There were 57 cases among participants with the lowest red-meat intake, and 113 in the group with the highest intake.

When the researchers accounted for other factors -- like age, weight, smoking and reported exercise habits -- participants who ate the most red meat were 79 percent more likely than those with the lowest intake to develop squamous cell carcinoma of the esophagus.

Red meat itself was not associated with gastric cardia cancer. But for one type of HCA, known as DiMelQx, men and women in the top 20 percent for intake had a 44 percent higher risk of gastric cardia cancer than those in the bottom 20 percent.

Red meat was not clearly linked to esophageal adenocarcinoma -- a cancer that arises in glandular cells in the lower esophagus, and is the more common form seen in the U.S. -- or to cancers in other parts of the stomach (non-cardia stomach cancers).

The different findings for different cancer subtypes are "not hugely surprising," Cross said, since they may differ in their underlying causes. She noted, for instance, that smoking and heavy drinking appear to be stronger risk factors for esophageal squamous cell cancer compared with adenocarcinoma, while obesity seems to be a greater factor in adenocarcinoma risk.

It is somewhat surprising, Cross said, that none of the HCA compounds the researchers assessed was related to esophageal squamous cell cancer, even though red-meat intake was. It is thought that, if red meat does contribute to the cancer, HCA exposure would be one reason why.

The bottom line, Cross said, is that further large, prospective studies are needed to see whether the relationship between red meat and the two cancers is real. She pointed out, though, that many health authorities already recommend that people limit their consumption of red and processed meats for the sake of their overall health.

The American Cancer Society estimates that about 21,000 cases of stomach cancer and 16,640 cases of esophageal cancer will be diagnosed in 2010.

SOURCE: link.reuters.com/vuv93q American Journal of Gastroenterology, online October 26, 2010.

| | コメント (0) | トラックバック (0)

より以前の記事一覧